ライフサイエンスコーパス: encephalomyelitis

1 ed susceptibility to experimental autoimmune encephalomyelitis.

2 ses, and exacerbated experimental autoimmune encephalomyelitis.

3 urine mouse model of experimental autoimmune encephalomyelitis.

4 munopathology during experimental autoimmune encephalomyelitis.

5 ulation of mice with experimental autoimmune encephalomyelitis.

6 igands could inhibit experimental autoimmune encephalomyelitis.

7 rotection of Tregs and experimental allergic encephalomyelitis.

8 ctivation and reduced severity of autoimmune encephalomyelitis.

9 ngham virus-dependent progressive multifocal encephalomyelitis.

10 autoimmune disease, experimental autoimmune encephalomyelitis.

11 y protects mice from experimental autoimmune encephalomyelitis.

12 protected mice from experimental autoimmune encephalomyelitis.

13 nd its animal model, experimental autoimmune encephalomyelitis.

14 esponses are seen in experimental autoimmune encephalomyelitis.

15 ggressive courses of experimental autoimmune encephalomyelitis.

16 ance the severity of experimental autoimmune encephalomyelitis.

17 r the development of experimental autoimmune encephalomyelitis.

18 reduced severity of experimental autoimmune encephalomyelitis.

19 % simultaneous TM&ON; 10% Acute disseminated encephalomyelitis.

20 to T cell-dependent experimental autoimmune encephalomyelitis.

21 and amelioration of experimental autoimmune encephalomyelitis.

22 relapsing-remitting experimental autoimmune encephalomyelitis.

23 es susceptibility to experimental autoimmune encephalomyelitis.

24 ple sclerosis model, experimental autoimmune encephalomyelitis.

25 rected at self-Ags during experimental acute encephalomyelitis.

26 gulation for host survival during alphavirus encephalomyelitis.

27 paired resolution of experimental autoimmune encephalomyelitis.

28 ctively, are required for fibrinogen-induced encephalomyelitis.

29 determining host survival during alphavirus encephalomyelitis.

30 oms and pathology of experimental autoimmune encephalomyelitis.

31 re seen in mice with experimental autoimmune encephalomyelitis.

32 nd its animal model, experimental autoimmune encephalomyelitis.

33 vivo development of experimental autoimmune encephalomyelitis.

34 system of mice with experimental autoimmune encephalomyelitis.

35 s system (CNS) inflammation, including viral encephalomyelitis.

36 sease: from multiple sclerosis to autoimmune encephalomyelitis.

37 suppression of ongoing experimental allergic encephalomyelitis.

38 e T cells and modulate experimental allergic encephalomyelitis.

39 ltiple sclerosis and experimental autoimmune encephalomyelitis.

40 induced arthritis or experimental autoimmune encephalomyelitis.

41 chronic or relapsing experimental autoimmune encephalomyelitis.

42 peutic reduction in, experimental autoimmune encephalomyelitis.

43 ive phases of murine experimental autoimmune encephalomyelitis.

44 mes (5 limbic encephalitis, 1 paraneoplastic encephalomyelitis, 1 paraneoplastic cerebellar degenerat

45 were encephalitis (52%), acute disseminated encephalomyelitis (12%), transverse myelitis (12%), and

46 297 prevented murine experimental autoimmune encephalomyelitis (a model of human multiple sclerosis)

47 t the progression of experimental autoimmune encephalomyelitis, a model for multiple sclerosis, even

48 (+) T cell-dependent experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis.

49 less-severe signs of experimental autoimmune encephalomyelitis, a murine model of MS, thus implicatin

50 scribed in children with acute disseminating encephalomyelitis (ADEM), but the clinical and neuroradi

51 ansverse myelitis (TM) or acute disseminated encephalomyelitis (ADEM), but the evidence for a causal

52 vous system diseases like acute disseminated encephalomyelitis (ADEM).

53 esistant Bc mice became susceptible to fatal encephalomyelitis after NSV infection.

54 PHTPP-mediated experimental autoimmune encephalomyelitis amelioration was canceled in mice with

55 suppression of ongoing experimental allergic encephalomyelitis (an MS animal model), and the disease

56 e are protected from experimental autoimmune encephalomyelitis, an animal model of MS, and Kv1.3-KO T

57 of mice subjected to experimental autoimmune encephalomyelitis, an animal model of MS.

58 ad in vivo impact on experimental autoimmune encephalomyelitis, an animal model of MS.

59 and protects mice from experimental allergic encephalomyelitis, an animal model of multiple sclerosis

60 ersensitivity and in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis

61 in vivo ameliorated experimental autoimmune encephalomyelitis and decreased the accumulation of CNS

62 were protected from experimental autoimmune encephalomyelitis and had impaired recruitment of Th17 c

63 to the induction of experimental autoimmune encephalomyelitis and had reduced productions of the gra

64 mi of mice at different stages of autoimmune encephalomyelitis and healthy controls.

65 immune responses during coronavirus-induced encephalomyelitis and in specifically promoting protecti

66 rbated the course of experimental autoimmune encephalomyelitis and increased macrophage infiltration

67 g/remitting model of experimental autoimmune encephalomyelitis and is neuroprotective.

68 ned the induction of experimental autoimmune encephalomyelitis and reduced basal TCR signaling in per

69 e severe symptoms of experimental autoimmune encephalomyelitis and reduced proportions of IL-10(+) Tr

70 of actively induced experimental autoimmune encephalomyelitis and salt-sensitive hypertension by mod

71 ive immunity against experimental autoimmune encephalomyelitis and suppressed IFN-gamma and IL-17 exp

72 em, markedly reduced experimental autoimmune encephalomyelitis and was 10-fold more potent than the f

73 ica spectrum disorder and acute disseminated encephalomyelitis) and from non-demyelinating disorders

74 reactions, relapsing experimental autoimmune encephalomyelitis, and antibody responses against coagul

75 m disorders and relapsing acute disseminated encephalomyelitis, and characterizing cohorts for antibo

76 ogic function in the experimental autoimmune encephalomyelitis animal model of multiple sclerosis was

77 -induced glomerulonephritis and experimental encephalomyelitis are attenuated in ICER/CREM-deficient

78 and its animal model experimental autoimmune encephalomyelitis, are neuroinflammatory diseases driven

79 signs of disease in experimental autoimmune encephalomyelitis, as well as maintain normoglycemia in

80 and private TCRbeta derived from autoimmune encephalomyelitis-associated TCR.

81 IL4I1 into mice with experimental autoimmune encephalomyelitis at disease onset significantly reverse

82 ntation in mice with experimental autoimmune encephalomyelitis at high resolution.

83 glycoprotein-induced experimental autoimmune encephalomyelitis, B7-H1-Ig exhibited a significant and

84 with MOG to promote experimental autoimmune encephalomyelitis because NFM-deficient synonymous with

85 from lethal neurotropic coronavirus-induced encephalomyelitis by accelerating but not enhancing the

86 Melioidosis with encephalomyelitis can result in severe residual disabili

87 eveloped more severe experimental autoimmune encephalomyelitis, characterized by increased lymphocyte

88 Remarkably, in experimental autoimmune encephalomyelitis, cholesterol supplementation does not

89 he Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM), we re

90 ion people in the United States have myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

91 Myalgic encephalomyelitis/chronic fatigue syndrome is an unexpla

92 Disease Prevention and the Trans-NIH Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Research Work

93 Workshop: Advancing the Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome was cosponsor

94 cted animals against experimental autoimmune encephalomyelitis, decreasing Th17 cells and increasing

95 ing phenotype: those with acute disseminated encephalomyelitis demonstrated abnormal trajectories of

96 In an experimental autoimmune encephalomyelitis disease model of neurodegeneration in

97 Encephalomyelitis due to infection with mosquito-borne a

98 fers protection from experimental autoimmune encephalomyelitis (EAE) and does not lead to increased r

99 neurodegeneration in experimental autoimmune encephalomyelitis (EAE) and in in vitro studies regardin

100 m, for inhibition of experimental autoimmune encephalomyelitis (EAE) and induction of tolerance.

101 an important role in experimental autoimmune encephalomyelitis (EAE) and perhaps MS.

102 the pathogenesis of experimental autoimmune encephalomyelitis (EAE) and, ostensibly, in multiple scl

103 (MS) subjects and of experimental autoimmune encephalomyelitis (EAE) animals, limited information is

104 We used experimental autoimmune encephalomyelitis (EAE) as a model of T cell-mediated au

105 o the development of experimental autoimmune encephalomyelitis (EAE) as a result of an increase of pr

106 ution of established experimental autoimmune encephalomyelitis (EAE) can be achieved with myelin olig

107 In an experimental autoimmune encephalomyelitis (EAE) disease model, we found that OX4

108 ces inflammation and experimental autoimmune encephalomyelitis (EAE) disease scores via the ligand-ac

109 of AMPK exacerbates experimental autoimmune encephalomyelitis (EAE) disease severity.

110 pment of spontaneous experimental autoimmune encephalomyelitis (EAE) during adolescence and early you

111 differentiation and experimental autoimmune encephalomyelitis (EAE) has not been adequately studied.

112 (NPCs) in mice with experimental autoimmune encephalomyelitis (EAE) impairs the accumulation of infl

113 17 cells that induce experimental autoimmune encephalomyelitis (EAE) in animals.

114 Using experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice, a well-studied

115 nses and spontaneous experimental autoimmune encephalomyelitis (EAE) in mice with a susceptible genet

116 cells and exacerbate experimental autoimmune encephalomyelitis (EAE) in mice.

117 tes the induction of experimental autoimmune encephalomyelitis (EAE) in rhesus monkeys.

118 Following experimental autoimmune encephalomyelitis (EAE) induction, Treg-specific Il27ra(

119 Experimental autoimmune encephalomyelitis (EAE) is a valuable model for studying

120 sexual dimorphism in experimental autoimmune encephalomyelitis (EAE) is associated with copy number v

121 e sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE) is unclear.

122 relapsing-remitting experimental autoimmune encephalomyelitis (EAE) mice.

123 rupted, including an experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis and

124 ritis and in a mouse experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis.

125 Using the experimental autoimmune encephalomyelitis (EAE) model, we were able to study not

126 in macrophages in an experimental autoimmune encephalomyelitis (EAE) model.

127 in MS using a mouse experimental autoimmune encephalomyelitis (EAE) model.

128 We used the experimental autoimmune encephalomyelitis (EAE) models in the common marmoset an

129 e progression in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS.

130 the T cell-mediated experimental autoimmune encephalomyelitis (EAE) mouse model, suppress disease by

131 velopment, using the experimental autoimmune encephalomyelitis (EAE) mouse model.

132 d lymph nodes (LN) at the peak of autoimmune encephalomyelitis (EAE) or differentiated in vitro under

133 Experimental autoimmune encephalomyelitis (EAE) represents a reliable model of t

134 K2 (CK2) ameliorates experimental autoimmune encephalomyelitis (EAE) severity and relapse incidence.

135 rotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) using AhR knockout mice.

136 ltration by B cells, experimental autoimmune encephalomyelitis (EAE) was induced in transgenic mice t

137 m in which mice with experimental autoimmune encephalomyelitis (EAE) were administered a sublethal do

138 his using a model of experimental autoimmune encephalomyelitis (EAE) with hippocampal degeneration in

139 been explored using experimental autoimmune encephalomyelitis (EAE), a CD4 T cell-dependent animal m

140 ated the severity of experimental autoimmune encephalomyelitis (EAE), a disease model of multiple scl

141 clinical symptoms in experimental autoimmune encephalomyelitis (EAE), a model for early-phase MS.

142 tation protects from experimental autoimmune encephalomyelitis (EAE), a model of MS.

143 Experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (

144 sion and function in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS.

145 r Bhlhe40 to mediate experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple scler

146 he clinical signs of experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple scler

147 and thereby limited experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple scler

148 neuroinflammation in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple scler

149 ark Agouti rats with experimental autoimmune encephalomyelitis (EAE), a widely accepted preclinical m

150 UV light suppresses experimental autoimmune encephalomyelitis (EAE), a widely used animal model of M

151 pment or severity of experimental autoimmune encephalomyelitis (EAE), although exacerbating colitis i

152 eveloped more severe experimental autoimmune encephalomyelitis (EAE), an animal model of human multip

153 disease severity in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple scl

154 m of action of Ba in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple scl

155 g the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple scl

156 o reduce severity of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple scl

157 , and in response to experimental autoimmune encephalomyelitis (EAE), an animal model of the inflamma

158 ltiple sclerosis and experimental autoimmune encephalomyelitis (EAE), but how it impacts neuroinflamm

159 ing atypical form of experimental autoimmune encephalomyelitis (EAE), characterized by lesions, infla

160 s the development of experimental autoimmune encephalomyelitis (EAE), deletion of Rac1 in T cells exh

161 nd its animal model, experimental autoimmune encephalomyelitis (EAE), expansion of pathogenic, myelin

162 s TH17 cell-mediated experimental autoimmune encephalomyelitis (EAE), it also disrupts thymocyte deve

163 and the animal model experimental autoimmune encephalomyelitis (EAE), little attention has been focus

164 its mouse model, the experimental autoimmune encephalomyelitis (EAE), miRNA dysregulation has been ma

165 s are therapeutic in experimental autoimmune encephalomyelitis (EAE), reducing paralysis and inflamma

166 t animals undergoing experimental autoimmune encephalomyelitis (EAE), the animal model of MS, resulte

167 +)) T cells promotes experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sc

168 Experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sc

169 ic T cell subsets in experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sc

170 ltiple sclerosis and experimental autoimmune encephalomyelitis (EAE), the C-C chemokine receptor 6 (C

171 nd its animal model, experimental autoimmune encephalomyelitis (EAE), the mechanisms of how these cel

172 ific role of TSPO in experimental autoimmune encephalomyelitis (EAE), the most studied animal model o

173 utically ameliorates experimental autoimmune encephalomyelitis (EAE), the mouse model of MS.

174 ells and exacerbated experimental autoimmune encephalomyelitis (EAE), the principal model of MS.

175 murine model of MS, experimental autoimmune encephalomyelitis (EAE), to evaluate the hypothesis that

176 tenuated severity of experimental autoimmune encephalomyelitis (EAE).

177 nd its animal model, experimental autoimmune encephalomyelitis (EAE).

178 g the MS mouse model experimental autoimmune encephalomyelitis (EAE).

179 type of the MS model experimental autoimmune encephalomyelitis (EAE).

180 endent protection in experimental autoimmune encephalomyelitis (EAE).

181 nd its animal model, experimental autoimmune encephalomyelitis (EAE).

182 relapsing-remitting experimental autoimmune encephalomyelitis (EAE).

183 cell-driven model of experimental autoimmune encephalomyelitis (EAE).

184 CNS) inflammation in experimental autoimmune encephalomyelitis (EAE).

185 ent of the MS model, experimental autoimmune encephalomyelitis (EAE).

186 ltiple sclerosis and experimental autoimmune encephalomyelitis (EAE).

187 n (MOG)35-55-induced experimental autoimmune encephalomyelitis (EAE).

188 relapsing-remitting experimental autoimmune encephalomyelitis (EAE).

189 rodent counterpart, experimental autoimmune encephalomyelitis (EAE).

190 ting activity on the Experimental Autoimmune Encephalomyelitis (EAE).

191 ytokine IFN-gamma in experimental autoimmune encephalomyelitis (EAE).

192 and are resistant to experimental autoimmune encephalomyelitis (EAE).

193 nesis of colitis and experimental autoimmune encephalomyelitis (EAE).

194 ecreased severity of experimental autoimmune encephalomyelitis (EAE).

195 autoimmunity model, experimental autoimmune encephalomyelitis (EAE).

196 multiple sclerosis, experimental autoimmune encephalomyelitis (EAE).

197 more susceptible to experimental autoimmune encephalomyelitis (EAE).

198 multiple sclerosis and experimental allergic encephalomyelitis (EAE).

199 d of its mouse model experimental autoimmune encephalomyelitis (EAE).

200 multiple sclerosis, experimental autoimmune encephalomyelitis (EAE).

201 of C57BL/6J mice to experimental autoimmune encephalomyelitis (EAE).

202 and its animal model experimental autoimmune encephalomyelitis (EAE).

203 ferred resistance to experimental autoimmune encephalomyelitis (EAE).

204 he manifestations of experimental autoimmune encephalomyelitis (EAE).

205 spinal cord, during experimental autoimmune encephalomyelitis (EAE).

206 idely used MS model, experimental autoimmune encephalomyelitis (EAE).

207 for the treatment of experimental autoimmune encephalomyelitis (EAE).

208 and the mouse model experimental autoimmune encephalomyelitis (EAE).

209 nd its animal model, experimental autoimmune encephalomyelitis (EAE).

210 responses, including experimental autoimmune encephalomyelitis (EAE).

211 nd its animal model, experimental autoimmune encephalomyelitis (EAE); however, the function of RISCs

212 ne diseases, such as experimental autoimmune encephalomyelitis (EAE); however, the involvement of IL-

213 ing paralysis during experimental autoimmune encephalomyelitis (EAE); instead, Nlrp12(-/-) mice devel

214 ack myelin sheath in experimental autoimmune encephalomyelitis (EAE, an animal model for multiple scl

215 tion associated with experimental autoimmune encephalomyelitis (EAE; a mouse model of multiple sclero

216 multiple sclerosis [experimental autoimmune encephalomyelitis, (EAE)] and a stabilized version of mo

217 odel of the disease (experimental autoimmune encephalomyelitis; EAE), but the mechanisms remain obscu

218 hepatitis virus (JHMV) resulted in an acute encephalomyelitis, followed by demyelination similar in

219 cells can ameliorate experimental autoimmune encephalomyelitis following transfer to wild-type recipi

220 at characterizing the pathogenesis of viral encephalomyelitis for the development of novel medical c

221 a mouse model of MS, experimental autoimmune encephalomyelitis, guanabenz alleviates clinical symptom

222 s in mouse models of autoimmune diabetes and encephalomyelitis have indicated that the selective deli

223 immune diseases like experimental autoimmune encephalomyelitis; however, its role in the pathogenesis

224 When subjected to experimental autoimmune encephalomyelitis, IL-17R-signaling-deficient mice demon

225 ctive local Ab within the CNS following JHMV encephalomyelitis.IMPORTANCE CD19 activation is known to

226 patients, EV71 neurological disease included encephalomyelitis in 23 (40%), brainstem encephalitis in

227 tic acid ameliorated experimental autoimmune encephalomyelitis in a therapeutic mouse model by regula

228 f Sindbis virus causes immune-mediated fatal encephalomyelitis in adult C57BL/6 mice but not in BALB/

229 d the development of experimental autoimmune encephalomyelitis in adulthood in male, but not female,

230 nhibitory effects on experimental autoimmune encephalomyelitis in both preventive and therapeutic mou

231 uces the severity of experimental autoimmune encephalomyelitis in hosts with wild-type but not Tim-1-

232 havirus infections are an important cause of encephalomyelitis in humans.

233 Moreover, experimental autoimmune encephalomyelitis in mice lacking 12/15-LO resulted in a

234 vivo and ameliorates experimental autoimmune encephalomyelitis in mice.

235 ition of GSK3 limits experimental autoimmune encephalomyelitis in mice.

236 chronic progressive experimental autoimmune encephalomyelitis in nonobese diabetic mice, an experime

237 promoted consistent experimental autoimmune encephalomyelitis induction, unlike mice challenged with

238 Viral encephalomyelitis is an important cause of age-dependent

239 Susceptibility to alphavirus encephalomyelitis is dependent on a variety of factors,

240 These studies show that fatal NSV-induced encephalomyelitis is immune mediated and that antagonist

241 In B6 mice, fatal encephalomyelitis is immune mediated rather than a direc

242 Neuronal cell death during fatal alphavirus encephalomyelitis is immune-mediated; however, the types

243 ated from JM with inflammatory demyelinating encephalomyelitis (JME).

244 The diagnosis of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is

245 Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is

246 ic collection of data on measures of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS).

247 expressed ANKRD55 in experimental autoimmune encephalomyelitis mice, with the higher fluorescence int

248 n MS murine model of experimental autoimmune encephalomyelitis, miR-155 controls Th cell function by

249 l (AA) and the mouse experimental autoimmune encephalomyelitis model (EAE).

250 In an in vivo experimental autoimmune encephalomyelitis model in which rapamycin suppresses di

251 administered in the experimental autoimmune encephalomyelitis model of MS.

252 n a nonhuman primate experimental autoimmune encephalomyelitis model that an EBV-related lymphocrypto

253 severity in a mouse experimental autoimmune encephalomyelitis model, demonstrating the viability of

254 an adoptive transfer experimental autoimmune encephalomyelitis model.

255 in a Th17-dependent experimental autoimmune encephalomyelitis model.

256 eak of disease in an experimental autoimmune encephalomyelitis mouse model of chronic progressive mul

257 s reminiscent of the experimental autoimmune encephalomyelitis mouse model with complete hindlimb par

258 oinflammation in the experimental autoimmune encephalomyelitis mouse model.

259 reported previously in patients with myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS),

260 ability to suppress experimental autoimmune encephalomyelitis or islet allograft rejection in murine

261 s of mice developing experimental autoimmune encephalomyelitis or lupus, respectively.

262 isplay an attenuated experimental autoimmune encephalomyelitis phenotype accompanied by decreased CNS

263 as did patients with non-acute disseminated encephalomyelitis presentations associated with lesions

264 tant to induction of experimental autoimmune encephalomyelitis, presumably by dampening the excessive

265 elination as well as experimental autoimmune encephalomyelitis, principal animal models of multiple s

266 of treatment in the experimental autoimmune encephalomyelitis rat model.

267 that TSSP increases experimental autoimmune encephalomyelitis severity by limiting central tolerance

268 The effect on experimental autoimmune encephalomyelitis severity was MHC class II allele depen

269 re, more definitive treatment for alphaviral encephalomyelitis should inhibit virus replication as we

270 re more susceptible to experimental allergic encephalomyelitis than mice sufficient for the HR (13R(+

271 less susceptible to experimental autoimmune encephalomyelitis than wild-type mice, and GPR174 defici

272 eveloped more severe experimental autoimmune encephalomyelitis than WT mice, displayed increased numb

273 nd adoptive-transfer experimental autoimmune encephalomyelitis that is characterized by reduced numbe

274 In experimental autoimmune encephalomyelitis, the animal model for MS, myelin-react

275 nstrated that during experimental autoimmune encephalomyelitis there are myelin oligodendrocyte glyco

276 optica spectrum disorder, acute disseminated encephalomyelitis, tumefactive demyelination, Balo's con

277 they induced severe experimental autoimmune encephalomyelitis upon adoptive transfer.

278 f MHV (JHMV), which causes acute and chronic encephalomyelitis, using a newly developed bacterial art

279 ntracerebral infection with Theiler's murine encephalomyelitis virus (TMEV) induces immune-mediated d

280 Intracerebral Theiler's murine encephalomyelitis virus (TMEV) infection in mice induces

281 Theiler's murine encephalomyelitis virus (TMEV) infection in mice results

282 We show that Theiler's murine encephalomyelitis virus (TMEV) infection of skeletal myo

283 Infection by Theiler's murine encephalomyelitis virus (TMEV) is a model for neurologic

284 persistently infected with Theiler's murine encephalomyelitis virus (TMEV) undergo apoptosis, result

285 lecules to brain atrophy in Theiler's murine encephalomyelitis virus (TMEV)-infected transgenic FVB m

286 with the Daniel's strain of Theiler's murine encephalomyelitis virus were treated with the FDA-approv

287 ested in the acute phase of Theiler's murine encephalomyelitis virus-induced demyelinating disease (T

288 roteoglycan accumulation in Theiler's murine encephalomyelitis virus-induced demyelinating disease.

289 of multiple sclerosis, the Theiler's murine encephalomyelitis virus-induced demyelinating disease.

290 sions in the spinal cord of Theiler's murine encephalomyelitis virus-infected mice.

291 sions in the spinal cord of Theiler's murine encephalomyelitis virus-infected mice.

292 cal and histological experimental autoimmune encephalomyelitis was observed in approximately 29% of i

293 of host susceptibility to fatal NSV-induced encephalomyelitis, we compared virus titers and immune r

294 multiple sclerosis, experimental autoimmune encephalomyelitis, we demonstrate that in vivo administr

295 tark contrast, using experimental autoimmune encephalomyelitis, we show that IL-17A(Cre)-mediated del

296 uch as arthritis and experimental autoimmune encephalomyelitis, where c-Rel promotes autoimmunity.

297 key brain induced by experimental autoimmune encephalomyelitis, which is the most-studied animal mode

298 were protected from experimental autoimmune encephalomyelitis, which was accompanied by a pronounced

299 dependently transfer experimental autoimmune encephalomyelitis (widely used as an animal model of MS)

300 r segmental-SPS, jerking-SPS and progressive encephalomyelitis with rigidity and myoclonus.